Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICT-121 DC vaccine
- Development stage
- Phase 1
- Lead developer
- EOM Pharmaceutical
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
ICT-121 DC vaccine is an investigational, patient-specific, cell-based immunotherapy designed to treat recurrent glioblastoma. The therapy uses autologous dendritic cells (DCs) derived from the patient's own monocytes. These cells are cultured and pulsed with purified peptides from the CD133 antigen—a protein overexpressed on many cancer stem cells and associated with resistance to chemotherapy and poor prognosis in glioblastoma. After preparation, the mature dendritic cells are administered intradermally back into the patient. The goal is to stimulate a cytotoxic T-cell immune response specifically targeting CD133-positive tumor cells, thereby promoting tumor cell lysis and potentially improving survival outcomes for patients with recurrent glioblastoma[2][4][6].
- Other names
- ICT-121 dendritic cell vaccineICT121 dendritic cell vaccineICT 121 dendritic cell vaccine
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on ICT-121 DC vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICT-121 DC vaccine.